ESMO

Truqap Extends Radiographic Progression-Free Survival in Some With Prostate Cancer

October 19th 2025, 5:09pm

Article

Adding Truqap to Zytiga, prednisone, and ADT extended radiographic progression-free survival by 7.5 months in PTEN-deficient prostate cancer.

Tiragolumab Plus Tecentriq Doesn’t Improve NSCLC Outcomes

October 19th 2025, 1:55am

Article

Consolidation tiragolumab plus Tecentriq does not improve progression-free survival in advanced lung cancer compared to Imfinzi.

HR+/HER2- Metastatic Breast Cancer Progression Improved With Sac-TMT

October 19th 2025, 1:25am

Article

Sac-TMT improved progression-free survival in patients with HR+/HER2– breast cancer.

Presurgical Enhertu Combo Elicits Response Benefit in HER2+ Early Breast Cancer

October 19th 2025, 12:28am

Article

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early breast cancer.

Similar Incidence of Second Primary Tumors After Libtayo or Placebo for CSCC

October 18th 2025, 11:32pm

Article

Postsurgical Libtayo and placebo showed similar rates of second primary tumors in high-risk CSCC

Enhertu Reduces Risk of Invasive Disease or Death in HER2+ Breast Cancer

October 18th 2025, 10:49pm

Article

Enhertu led to a 53% reduction in the risk of invasive disease or death versus Kadcyla in some patients with high-risk, HER2-positive breast cancer.

Postsurgical Opdivo Associated With Long-Term Activity in Melanoma

October 18th 2025, 9:26pm

Article

Adjuvant Opdivo significantly extended relapse-free survival in patients with resected stage advanced melanoma.

Keytruda Combo Improves Progression, Survival in Recurrent Ovarian Cancer

October 18th 2025, 8:16pm

Article

Clinical trial results showed favorable results with Keytruda-based therapy in this ovarian cancer population.

Imdelltra Improves Survival For Some With Small Cell Lung Cancer

October 18th 2025, 7:08pm

Article

Clinical trial data support the use of Imdelltra as a standard of care for all patients with second-line small cell lung cancer.

Lymphoma Survivors Find Fatigue Relief From Multidisciplinary Intervention

October 18th 2025, 6:29pm

Article

Lymphoma survivors with chronic fatigue participating in a multidisciplinary intervention program experienced benefits to fatigue and quality of life.